Familial Lipoprotein Lipase Deficiency - 13 Studies Found

Terminated : Extension to a Randomized, Double-blind, Placebo Controlled Study of LCQ908 in Subjects With Familial Chylomicronemia Syndrome.
: Familial Chylomicronemia Syndrome (FCS) (HLP Type I)
: 2012-04-27
: Drug: LCQ908
Completed : The APPROACH Study: A Study of Volanesorsen (Formerly IONIS-APOCIIIRx) in Patients With Familial Chylomicronemia Syndrome
: Familial Chylomicronemia Syndrome
: 2014-08-05
:
  • Drug: volanesorsen Other Names
Completed : A Randomized, Double-blind, Placebo Controlled Study to Assess Efficacy, Safety and Tolerability of LCQ908 in Subjects With Familial Chylomicronemia Syndrome
: Familial Chylomicronemia Syndrome (FCS)
: 2011-12-21
:
  • Drug: LCQ908 LCQ908 10 mg, LCQ
Completed : Safety and Efficacy in LPL-Deficient Subjects of AMT-011, an Adeno-Associated Viral Vector Expressing Human Lipoprotein Lipase [S447X]
: Familial Lipoprotein Lipase Deficiency
: 2010-04-22
:
  • Genetic: Alipogene Tiparvovec (AMT-011), Human LPL [S447X]

Completed : Efficacy and Safety of Human Lipoprotein Lipase (LPL)[S447X] Expressed by an Adeno-Associated Viral Vector in LPL-deficient Subjects
: Familial Lipoprotein Lipase Deficiency
: 2009-04-30
:
  • Genetic: Alipogene Tiparvovec (AMT-011), Human LPL [S447X]

Terminated : Duration of Effect of Alipogene Tiparvovec Treatment, Which Was Administered in Other Studies
: Hyperlipoproteinemia Type I
: 2011-09-28
Completed : Orlistat for the Treatment of Type I Hyperlipoproteinemia
:
  • Hyperlipoproteinemia Type I
  • Hypertriglyceridemia

: 2016-05-02
: Drug: Orlistat Orlistat is a gastric and pancreatic lipase inhibitor that is approved by the FDA for wei
Completed : The Approach Open Label Study: A Study of Volanesorsen (Formerly IONIS-APOCIIIRx) in Patients With Familial Chylomicronemia Syndrome
:
  • Familial Chylomicronemia Syndrome
  • Lipopro
    : 2016-01-12
    : Drug: Volanesorsen 300 mg volanesorsen Other Names:
Completed : Alipogene Tiparvovec for the Treatment of LPLD Patients
: LPL Deficiency
: 2016-05-10
:
  • Drug: alipogene tiparvovec A d
Not yet recruiting : Lipoprotein Lipase Enzyme Activity Assay Validation and Clinical Assessment
: Lipoprotein Lipase Deficiency
: 2016-01-12
: Drug: Heparin Participants will be given IV heparin in order to release lipoprotein lipase from capillar
Next >>>